First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry

ConclusionsThe new CoCr-BES showed low rates of MACE, MI, ci-TVR and ST at 9 months, similar to the BES arm in LEADERS.

Source: IJC Heart and Vasculature - January 28, 2020 Category: Cardiology Source Type: research